Provided by Tiger Trade Technology Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

351.00
-0.4800-0.14%
Post-market: 351.000.00000.00%19:30 EDT
Volume:674.73K
Turnover:235.82M
Market Cap:40.01B
PE:62.80
High:351.94
Open:347.82
Low:346.17
Close:351.48
52wk High:385.22
52wk Low:253.95
Shares:114.00M
Float Shares:80.95M
Volume Ratio:2.46
T/O Rate:0.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.59
EPS(LYR):2.47
ROE:14.66%
ROA:7.46%
PB:7.73
PE(LYR):142.11

Loading ...

Pharmaceutical Rally Continues: Gan&Lee Pharmaceuticals Hits Limit-Up, Beone Medicines Logs 6-Day Winning Streak; Huabao Funds' HK Medical and Innovation Drug ETFs Rise for Third Consecutive Session

Deep News
·
Aug 11

Beone Medicines : Jefferies Raises Target Price to $395 from $388

THOMSON REUTERS
·
Aug 11

CICC Retains Outperform Rating on BeiGene (06160) with HKD 266 Price Target

Stock News
·
Aug 11

BEONE MEDICINES Surges Over 4% in Morning Trading on Strategic Partnership with Revolution Medicines to Accelerate RAS Drug Development

Stock News
·
Aug 11

BeOne Medicines partners with Revolution Medicines for clinical development

TIPRANKS
·
Aug 10

BOCOM International Lifts BEONE MEDICINES Price Target to HKD 276, Maintains Buy Rating

Stock News
·
Aug 10

Goldman Sachs Competitor Adjusts BeOne Medicines Target Upward, Bullish Ratings Maintained

Deep News
·
Aug 09

BEONE MEDICINES Confirms External CMO Supply for Baiyueda, All Processes On Schedule

Deep News
·
Aug 07

BEONE MEDICINES: Approximately 95% of Pancreatic Cancer Cases Show KRAS Mutation, Around 20% Exhibit MTAP Deletion, Enabling Easy Identification of Overlapping Patient Groups

Deep News
·
Aug 07

BEONE MEDICINES Reports BRUKINSA Captures Over Half of New CLL/SLL Patient Share

Deep News
·
Aug 07

Beigene's GPC3x4-1BB Candidate Moves From Phase 1 to a Potential Pivotal Phase 2 Study in About 19 Months

Deep News
·
Aug 07

BEONE MEDICINES Halts Initial KRAS Inhibitor Project but Remains Active in RAS Field

Deep News
·
Aug 07

BEONE MEDICINES Plans to Unveil Preliminary CEA ADC Findings for Non-Small Cell Lung Cancer, Including Both Squamous and Non-Squamous Cases

Deep News
·
Aug 07

Movement Alert|BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.49% in Regular Trading, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices

Market Focus
·
Aug 07

Movement Alert|BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.48% in Pre-Market Trading, Q2 Earnings Significantly Beat Expectations as Multiple Institutions Raise Target Prices

Market Focus
·
Aug 07

Movement Alert|BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS Rises 5.16% Overnight, Q2 Earnings Beat Expectations as Multiple Institutions Raise Target Prices

Market Focus
·
Aug 07

CLSA Maintains Outperform Rating on BEONE MEDICINES, Raises Price Target to HK$321.70

Deep News
·
Aug 07

BEONE MEDICINES Surges Over 4% Intraday as UOB Kay Hian Raises Target Price to HK$265

Deep News
·
Aug 07

BeOne Medicines (ONC) Earnings Beat And Higher Guidance Leave Valuation In Focus

Simply Wall St.
·
Aug 07

Hong Kong Stock Moves: BEONE MEDICINES Surges Nearly 4% After Earnings, Adjusted Net Profit Up 111% YoY in First Half, Solid Tumor Progress Noted

Stock News
·
Aug 07